title: Magnesium sulfate for preterm labor and preterm birth.
abstract: Approximately half of the more than 500,000 preterm births each year result from preterm labor. Tocolytic therapy continues to be the focus of treatment of these women. Although a variety of tocolytics are used in clinical practice, magnesium sulfate remains one of the most commonly used agents. Magnesium sulfate has also been the focus of recent research for its potential neuroprotective effects for neonates born preterm. Evaluation of 19 randomized clinical trials reveals that magnesium sulfate tocolysis does not reduce the frequencies of delivery within 48 hours, 7 days, or early/late preterm birth, and is not associated with improvements in newborn morbidities or mortality. No other tocolytic class resulted in improved newborn outcomes when compared with magnesium sulfate tocolysis. We conclude that it is appropriate to withhold tocolysis with magnesium sulfate or other agents from women presenting in preterm labor as newborn benefit has not been demonstrated with such treatment. If initiated to achieve time for antenatal corticosteroid administration, or for other acute reasons, treatment can be discontinued once these goals have been achieved or if labor subsides before then. Because brief pregnancy prolongation is unlikely to improve newborn outcomes after corticosteroid administration has been completed, it is appropriate to withhold magnesium sulfate tocolysis from women with recurrent preterm labor thereafter. If magnesium sulfate is given for neuroprotection, a protocol from one of the three major trials that have demonstrated benefits should be used.
authors.affiliation: From the Department of Obstetrics & Gynecology, MetroHealth Medical Center, Cleveland, Ohio.
authors.forename: Brian M
authors.initials: BM
authors.lastname: Mercer
authors.forename: Amy A
authors.initials: AA
authors.lastname: Merlino
mesh_terms: D001927:Brain Diseases / Q000517:prevention & control; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D015149:Tocolytic Agents / Q000627:therapeutic use*
chemical_list: D015149:Tocolytic Agents; D008278:Magnesium Sulfate
references.citation: Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S, et al. Births: final data for 2006. National vital statistics reports. Vol 57. Hyattsville, MD: National Center for Health Statistics; 2009. p.1–104.
references.citation: Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001;107:E1.
references.citation: Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental outcomes of extremely low birth weight infants <32 weeks' gestation between 1993 and 1998. Pediatrics 2005;116:635–43.
references.citation: Hack M, Flannery DJ, Schluchter M, Cartar L, Borawski E, Klein N. Outcomes in young adulthood for very-low-birth-weight infants. N Engl J Med 2002;346:149–57.
references.citation: Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD. National Institute of Child Health and Human Development Neonatal Research Network. Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993-1999. Pediatrics 2005;115:1645–51.
references.citation: Meis PJ, Ernest JM, Moore ML. Causes of low birth weight births in public and private patients. Am J Obstet Gynecol 1987;156:1165–8.
references.citation: Tucker JM, Goldenberg RL, Davis RO, Copper RL, Winkler CL, Hauth JC. Etiologies of preterm birth in an indigent population: is prevention a logical expectation? Obstet Gynecol 1991;77:343–7.
references.citation: Mercer BM, Goldenberg RL, Moawad AH, Meis PJ, Iams JD, Das AF, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol 1999;181:1216–21.
references.citation: Berkman ND, Thorp Jr, JM Hartmann KE, Lohr KN, Anjolie E, Idicula AE, et al. Management of preterm labor. Evidence Report/Technology Assessment No. 18. Research Triangle Institute. AHRQ Publication No. 01-E021. Rockville (MD): Agency for Healthcare Research and Quality; 2000.
references.citation: Berkman ND, Thorp JM Jr, Lohr KN, Carey TS, Hartmann KE, Gavin NI, et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol 2003;188:1648–59.
references.citation: Elin RJ. Magnesium: the fifth but forgotten electrolyte. Am J Clin Pathol 1994;102:616–22.
references.citation: Wolfe FI, Torsello A, Fasanella S, Cittadini A. Cell physiology of magnesium. Mol Aspects Med 2003;24:11–26.
references.citation: Standing committee on the scientific evaluation of dietary reference intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorous, magnesium, vitamin D, and Fluoride. Washington, DC: National Academies Press; 1997. p. 190–249.
references.citation: Kurzel RB. Serum magnesium levels in pregnancy and preterm labor. Am J Perinatol 1991;8:119–27.
references.citation: Weissberg N, Schwartz G, Shemesh O, Brooks BA, Algur N, Eylath U, et al. Serum and mononuclear cell potassium, magnesium, sodium and calcium in pregnancy and labour and their relation to uterine muscle contraction. Magnes Res 1992;5:173–7.
references.citation: Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anesthes 1999;83:302–20.
references.citation: Quamme GA, Dirks JH. The physiology of renal magnesium handling. Ren Physiol 1986;9:257–69.
references.citation: Kumar D, Zourlas PA, Barnes AC. In vitro and in vivo effects of magnesium sulfate on human uterine contractility. Am J Obstet Gynecol 1963;86:1036–40.
references.citation: Hall DG, Mcgaughey Jr, HS Corey EL, Thornton WN. The effects of magnesium therapy on the duration of labor. Am J Obstet Gynecol 1959;78:27–32.
references.citation: Fomin VP, Gibbs SG, Vanam R, Morimiya A, Hurd WW. Effect of magnesium sulfate on contractile force and intracellular calcium concentration in pregnant human myometrium. Am J Obstet Gynecol 2006;194:1384–90.
references.citation: Phillippe M. Cellular mechanisms underlying magnesium sulfate inhibition of phasic myometrial contractions. Biochem Biophys Res Commun 1998;252:502–7.
references.citation: Tica VI, Tica AA, Carlig V, Banica OS. Magnesium ion inhibits spontaneous and induced contractions of isolated uterine muscle. Gynecol Endocrinol 2007;23:368–72.
references.citation: Berger R, Garnier Y, Jensen A. Perinatal brain damage: underlying mechanisms and neuroprotective strategies. J Soc Gynecol Investig 2002;9:319–28.
references.citation: Hutchison HT, Nichols MM, Kuhn CR, Vasicka A. Effects of magnesium sulphate on uterine contractility, intrauterine fetus, and infant. Am J Obstet Gynecol 1964;88:747–58.
references.citation: Lyell DJ, Pullen K, Campbell L, Ching S, Druzin ML, Chitkara U, Burrs D, Caughey AB, El-Sayed YY. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstet Gynecol 2007;110:61–7.
references.citation: Cotton DB, Strassner HT, Hill LM, Schifrin BS, Paul RH. Comparison of magnesium sulfate, terbutaline and a placebo for inhibition of preterm labor. A randomized study. J Reprod Med 1984;29:92–7.
references.citation: Cox SM, Sherman ML, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990;163:767–72.
references.citation: Fox MD, Allbert JR, McCaul JF, Martin RW, McLaughlin BN, Morrison JC. Neonatal morbidity between 34 and 37 weeks' gestation. J Perinatol 1993;13:349–53.
references.citation: How HY, Zafaranchi L, Stella CL, Recht K, Maxwell RA, Sibai BM, et al. Tocolysis in women with preterm labor between 32 0/7 and 34 6/7 weeks of gestation: a randomized controlled pilot study. Am J Obstet Gynecol 2006;194:976–81.
references.citation: Miller JM, Keane MWD, Horger EO. Comparison of magnesium sulfate and terbutaline for the arrest of premature labor. J Reprod Med 1982;27:348–51.
references.citation: Hollander DI, Nagey DA, Pupkin MJ. Magnesium sulfate and ritodrine hydrochloride: a randomized comparison. Am J Obstet Gynecol 1987;156:631–7.
references.citation: Wilkins IA, Lynch L, Mehalek KE, Berkowitz GS, Berkowitz RL. Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. Am J Obstet Gynecol 1988;159:685–9.
references.citation: Chau AC, Gabert HA, Miller JM. A prospective comparison of terbutaline and magnesium for tocolysis. Obstet Gynecol 1992;80:847–51.
references.citation: Floyd RC, McLauglin BN, Perry Jr, KG Martin RW, Sullivan CA, Morrison JC. Magnesium sulfate or nifedipine hydrochloride for acute tocolysis of preterm labor: efficacy and side effects. J Matern Fetal Invest 1995;5:25–9.
references.citation: Glock JL, Morales WJ. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: A randomized study. Am J Obstet Gynecol 1993;169:960–4.
references.citation: Haghighi L. Prevention of preterm delivery: nifedipine or magnesium sulfate. Int J Gynecol Obstet 1999;66:297–8.
references.citation: Larmon JE, Ross BS, May WL, Dickerson GA, Fischer RG, Morrison JC. Oral nicardipine versus intravenous magnesium sulfate for the treatment of preterm labor. Am J Obstet Gynecol 1999;181:1432–7.
references.citation: Morales WJ, Madhav H. Efficacy and safety of indomethacin compared with magnesium sulfate in the management of preterm labor: a randomized study. Am J Obstet Gynecol 1993;169:97–102.
references.citation: Parilla BV, Tamura RK, Cohen LS, Clark E. Lack of effect of antenatal indomethacin on fetal cerebral blood flow. Am J Obstet Gynecol 1997;176:1166–9.
references.citation: Schorr SJ, Ascarelli MH, Rust OA, Ross EL, Calfee EL, Perry KG, et al. A Comparative study of ketorolac (toradol) and magnesium sulfate for arrest of preterm labor. South Med J 1998;91:1028–32.
references.citation: McWhorter J, Carlan S, O'Leary T, Richici K, O'Brien W. Rofecoxib versus magnesium sulfate to arrest preterm labour: a randomized trial. Obstet Gynecol 2004;103:923–30.
references.citation: Borna S, Saeidi FM. Celecoxib versus magnesium sulfate to arrest preterm labor: randomized trial. J Obstet Gynaecol Res 2007;33:631–4.
references.citation: Steer CM, Petrie RH. A comparison of magnesium sulfate and alcohol for the prevention of premature labor. Am J Obstet Gynecol 1977;129:1–4.
references.citation: Aramayo FJ, Martinez FJ, Rosales CL. Tocolytic therapy with magnesium sulfate and terbutaline for inhibition of premature labor [Terapia tocolitica con sulfato de magnesio y terbutalina para la inhibicion del trabajo de parto pretermino]. Ginecol y Obstet de Mexico 1990;58:265–9.
references.citation: Armson BA, Samuels P, Miller F, Verbalis J, Main EK. Evaluation of maternal fluid dynamics during tocolytic therapy with ritodrine hydrochloride and magnesium sulfate. Am J Obstet Gynecol 1992;167:758–65.
references.citation: Beall MH, Edgar BW, Paul RM, Smith-Wallace T. A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm labor. Am J Obstet Gynecol 1985;153:854–9.
references.citation: El-Sayed YY, Riley ET, Holbrook RH, Cohen SE, Chitkara U, Druzin ML. Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labor. Obstet Gynecol 1999;93:79–83.
references.citation: Ferguson JE, Hensleigh PA, Kredenster D. Adjunctive use of magnesium sulfate with ritodrine for preterm labour. Am J Obstet Gynecol 1984;148:166–71.
references.citation: Hatjis CG, Swain M, Nelson LH, Meis PJ, Ernest JM. Efficacy of combined administration of magnesium sulfate and ritodrine in the treatment of premature labor. Obstet Gynecol 1987;69:317–22.
references.citation: How HY, Cook CR, Cook VD, Miles DE, Spinnato JA. Preterm premature rupture of membranes: aggressive tocolysis versus expectant management. J Matern Fetal Med 1998;7:8–12.
references.citation: Ma L. Magnesium sulfate in prevention of preterm labor. Chung Hua I Hsueh Tsa Chih Taipei 1992;72:158–61.
references.citation: Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186:1111–8.
references.citation: Newton ER, Shields L, Ridgway LE, Berkus MD, Elliott BD. Combination antibiotics and indomethacin in idiopathic preterm labor: a randomized double-blind clinical trial. Am J Obstet Gynecol 1991;165:1753–9.
references.citation: Ogburn PL, Hansen CA, Williams PP, Butler JC, Joseph MS, Julian TM. Magnesium sulfate and B-mimetic dual-agent tocolysis in preterm labor after single-agent failure. J Reprod Med 1985;30:583–7.
references.citation: Sciscione A, Gorman R, Schlossman P, Colmorgen G. A randomized prospective study of intravenous magnesium sulfate, ritodrine, and subcutaneous terbutaline as treatments for preterm labor. Am J Obstet Gynecol 1993;168:376.
references.citation: Tchilinguirian NG, Najem R, Sullivan GB, Craparo FJ. The use of ritodrine and magnesium sulfate in the arrest of premature labor. Int J Gynaecol Obstet 1984;22:117–23.
references.citation: Weiner CP, Renk K, Klugman M. The therapeutic efficacy and cost-effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes. Am J Obstet Gynecol 1988;159:216–22.
references.citation: Wischnik A, Hettenbach A, Schmidt R, Zieger W, Hug G, Melchert F. The effect of magnesium sulfate on volume balance in tocolysis with the betamimetic agent fenoterol. Z Geburtshilfe Perinatol 1989;193:251–5.
references.citation: Zhu B, Fu Y. Treatment of preterm labor with ritodrine (translation). Chung Hua Fu Chan Ko Tsa Chih 1996;31:721–3.
references.citation: Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J Perinat Med 1984;12:25–9.
references.citation: Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Br J Obstet Gynaecol 1999;106:467–73.
references.citation: Papatsonis DN, Van Geijn HP, Adèr HJ, Lange FM, Bleker OP, Dekker GA. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol 1997;90:230–4.
references.citation: Rayamajhi R, Pratap K. A comparative study between nifedipine and isoxsuprine in the suppression of preterm labour. Kathmandu Univ Med J 2003;1:185–90.
references.citation: Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95:263–9.
references.citation: Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996;276:1805–10.
references.citation: Paneth N, Jetton J, Pinto-Martin J, Susser M. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemorrhage Study Analysis Group. Pediatrics 1997;99:E1.
references.citation: Grether JK, Hoogstrate J, Walsh-Greene E, Nelson KB. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. Am J Obstet Gynecol 2000;183:717–25.
references.citation: Boyle CA, Yeargin-Allsopp M, Schendel DE, Holmgreen P, Oakley GP. Tocolytic magnesium sulfate exposure and risk of cerebral palsy among children with birth weights less than 1,750 grams. Am J Epidemiol 2000;152:120–4.
references.citation: Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877–90.
references.citation: Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007;114:289–99.
references.citation: Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997;350:1517–8.
references.citation: Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290:2669–76.
references.citation: Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque Hellot MF, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007;114:310–8.
references.citation: Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359:895–905.
references.citation: Marret S, Marpeau L, Bénichou J. Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics 2008;121:225–6.